Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Regentis Biomaterials Ltd.
No Price
Closing Price XASE 29.04.2026:
2,93 USD
29.04.2026 14:27
Current Prices from Regentis Biomaterials Ltd.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
AMEX
RGNT
USD
29.04.2026 14:27
2,93 USD
-0,07 USD
-2,30 %
Company Profile for Regentis Biomaterials Ltd. Share
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions that restore the health and enhance quality of life of patients. Its lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries and articular knee cartilage. The company focuses on developing orthopedic treatments using its Gelrin platform that is based on degradable hydrogel implants to regenerate damaged or diseased tissue. Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.
